Suvorexant: all 63 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Suvorexant 3 - PE-PCNot yet recruitingNCT07686731Phase 4
• Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related DrinkingRecruitingNCT07214207Phase 2
• Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical TrialRecruitingNCT06854224Phase 2
• The Effects of Orexin Antagonism on Fear Extinction in PTSDNot yet recruitingNCT06788522Phase 4
• Suvorexant for Treatment of AUD and PTSDRecruitingNCT06679062Phase 2
• A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)RecruitingNCT06655883Phase 3
• Suvorexant for Alcohol Use Disorder (AUD): Neural MechanismsRecruitingNCT06484075Phase 1/2
• Suvorexant and AlcoholRecruitingNCT06326684Early Phase 1
• Trial of Suvorexant for Sleep in Children With AutismRecruitingNCT05546554Phase 2
• Sleep Trial to Prevent Alzheimer's DiseaseRecruitingNCT04629547Phase 2
• Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic StressRecruitingNCT03642028Phase 4
• Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer SurvivorsTerminatedNCT06162663Phase 4Results posted
• Efficacy of Suvorexant on Post-operative Sleep DisturbanceCompletedNCT05823844Phase 4Results posted
• REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With SuvorexantCompletedNCT05733286Phase 2Results posted
• The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use DisorderTerminatedNCT05711862Phase 2Results posted
• Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use DisorderCompletedNCT05656534Early Phase 1Results posted
• Treating Insomnia and Improving Metabolic Health in Midlife Women With InsomniaCompletedNCT05593653Phase 4Results posted
• Suvorexant for Opioid/Stimulant Co-useCompletedNCT05546515Phase 2Results posted
• Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic InsomniaCompletedNCT04706091Phase 4Results posted
• Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)CompletedNCT04571944Phase 3Results posted
• Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use DisorderCompletedNCT04287062Phase 2Results posted
• Suvorexant to Reduce Symptoms of Nicotine UseCompletedNCT04234997Phase 2Results posted
• Medication Development in Alcoholism: Suvorexant Versus PlaceboCompletedNCT04229095Phase 2Results posted
• Suvorexant and Sleep/Delirium in ICU PatientsCompletedNCT04092894Phase 4Results posted
• Suvorexant and CocaineCompletedNCT03937986Early Phase 1Results posted
• Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 DiabetesCompletedNCT03818581Phase 4Results posted
• Medical Management of Sleep Disturbance During Opioid TaperingCompletedNCT03789214Phase 2Results posted
• The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open TrialCompletedNCT03412591Phase 2/3Results posted
• Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly InsomniacsCompletedNCT03312517Phase 4Results posted
• A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and InsomniaCompletedNCT03110315Phase 4Results posted
• Sleep Quality and Amyloid-Beta KineticsCompletedNCT03077620Not applicableResults posted
• Efficacy of Suvorexant in the Treatment of Hot Flash-associated InsomniaCompletedNCT03034018Phase 4Results posted
• Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress DisorderCompletedNCT02849548Phase 4Results posted
• To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With InsomniaCompletedNCT02849184Phase 4Results posted
• Role of the Orexin Receptor System in Stress, Sleep and Cocaine UseCompletedNCT02785406Phase 2Results posted
• Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)CompletedNCT02750306Phase 3Results posted
• A Pilot Study of Suvorexant for Insomnia in Parkinson DiseaseCompletedNCT02729714Phase 4Results posted
• Suvorexant and Trauma Related InsomniaCompletedNCT02704754Phase 4Results posted
• Suvorexant in Insomnia Co-morbid With FibromyalgiaTerminatedNCT02684136Phase 4Results posted
• The Role of Orexin in Human Panic DisorderCompletedNCT02593682Phase 4Results posted
• Efficacy of Suvorexant to Treat Insomnia Related to Bipolar DisorderCompletedNCT02527564Phase 4Results posted
• Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift WorkersCompletedNCT02491788Phase 4Results posted
• Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)CompletedNCT01300455Phase 1Results posted
• Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)CompletedNCT01293006Phase 1Results posted
• Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)CompletedNCT01097629Phase 3Results posted
• Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)CompletedNCT01097616Phase 3Results posted
• Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)CompletedNCT01059851Phase 1Results posted
• Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)CompletedNCT01043926Phase 1Results posted
• A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)CompletedNCT01021813Phase 3Results posted
• Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)CompletedNCT00792298Phase 2Results posted
• Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer PatientsWithdrawnNCT06834386Phase 4
• Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)CompletedNCT06584942Phase 4
• Suvorexant as an Adjunct to Buprenorphine in Persons Who Use FentanylCompletedNCT05145764Phase 2
• A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled StudyActive, not recruitingNCT04273776Early Phase 1
• Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use DisorderTerminatedNCT04262193Phase 2
• Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)CompletedNCT04014387Phase 4
• Targeting Orexin to Treat Nicotine DependenceCompletedNCT03999099Phase 1
• Suvorexant in the Management Comorbid Sleep Disorder and Alcohol DependenceTerminatedNCT03897062Phase 2
• Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic InsomniaStatus unknownNCT03768713Phase 4
• Suvorexant (Belsomra) for the Treatment of Bipolar Depression With InsomniaWithdrawnNCT03764683Phase 4
• Treatment of Restless Legs Syndrome With the Hypocretin Antagonist SuvorexantStatus unknownNCT03755310Phase 2
• A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual InsomniaStatus unknownNCT02669030Phase 4
• A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)CompletedNCT01311882Phase 1

← Suvorexant overview